N/A
Completed N=3,011
A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain.
Source: ClinicalTrials.gov NCT06291831 ↗Enrolled (actual)
3,011
Serious AEs
0.0%
Results posted
Aug 2025
Primary outcomePrimary: Number of Participants Classified Based on Education
Summary
The purpose of this study is to collect information on the:
* general information of a group of people such as their age, sex
* clinical information of the patients such as any other illness before having COVID 19.
* the number of COVID-19 patients who meet and follow the most up to date World Health Organization (WHO) recommendations for medication to treat COVID-19 (such as version 14, published 10Nov2023) compared to Kingdom of Bahrain national recommendations
* adult COVID-19 patients' health care resource use and outcomes within the 28-day period In adult patients with COVID-19 who have been prescribed nirmatrelvir and ritonavir treatment.
This study will be conducted in the Kingdom of Bahrain. The study will capture information of the adult COVID-19 outpatients and inpatients who have been prescribed nirmatrelvir, ritonavir treatment and those not treated with nirmatrelvir, ritonavir.
This study will have about 3000 patients treated with Paxlovid™ therapy and 1000 were not. The study will involve collection of patient information from medical records. The information collected can be either from papers or from computers.
The study will include patient information of those who:
* had COVID-19 infection during the study period from 16 February 2022 to 30 November 2022.
* are 18 years of age or older. This study will help to inform decision-making on use of Paxlovid at the national level.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Classified Based on Education |
— | — |
| PRIMARY Number of Participants Classified Based on Employment Status |
— | — |
| PRIMARY Height |
— | — |
| PRIMARY Weight |
— | — |
| PRIMARY Body Mass Index (BMI) |
29; 29 | — |
| PRIMARY Number of Participants Classified Based on Smoking Status |
— | — |
| PRIMARY Number of Participants With at Least 1 Pre-existing Comorbidities |
1709; 920 | — |
| PRIMARY Number of Participants Who Took at Least 1 Concomitant Medications for Pre-existing Comorbidities |
— | — |
| PRIMARY Number of Participants Who Used Antibiotics |
530; 320; 118; 103 | — |
| SECONDARY Number of Participants With Hospitalization for Any Cause |
137; 123 | — |
| SECONDARY Number of Participants With Intensive Care Unit (ICU) Admission for Any Cause |
3; 1 | — |
| SECONDARY Number of Participants Classified According to Length of Stay (LOS) in ICU for Any Cause |
0; 1; 1; 0; 2; 0 | — |
| SECONDARY Number of Participants With Yes/no Questionnaire on Outpatient Visits |
— | — |
| SECONDARY Number of Participants With Emergency Room (ER) Visits for Any Cause |
298; 155 | — |
| SECONDARY Number of Participants With Supplemental Oxygen Usage |
21; 11 | — |
| SECONDARY Number of Participants With Vasopressor Use |
— | — |
| SECONDARY Number of Participants Who Used Invasive Mechanical Ventilation (IMV) |
0; 1 | — |
Eligibility Criteria
Inclusion Criteria
Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:Age 18 years and older Patients with a diagnosis of COVID-19 whose information can be extracted from the I-Seha database
Exclusion Criteria
There are no exclusion criteria for this study.
Data sourced from ClinicalTrials.gov (NCT06291831). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.